Placebo Group

Aminocaproic acid is an antifibrinolytic drug

Aminocaproic Acid Group

HOE 140 Group

Total

Sex: Female, Male

Region of Enrollment

Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate.

Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.

Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.

HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.

Allogenic Blood Product Transfusion Risk

Units of Packed Red Blood Cells Transfused

Units of Packed Red Blood Cells Transfused During Hospitalization

Units of Plasma Transfused During Hospitalization

Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2.

Inflammatory Response as Measured by Interleukin-6

D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1

essential hypertension/protease

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

La base de datos de hierbas medicinales más completa respaldada por la ciencia